Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noriko Isobe

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Scientific Reports|October 10, 2020
Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-AmericansNathan Nakatsuka, Nick Patterson, Nikolaos A Patsopoulos, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 11, 2023
Anti-LGI4 Antibody Is a Novel Juxtaparanodal Autoantibody for Chronic Inflammatory Demyelinating PolyneuropathyXu Zhang, Jun-Ichi Kira, Hidenori Ogata, et al.
Brain, Behavior, and Immunity|July 10, 2024
A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of α-synuclein oligomers and phosphorylated α-synuclein aggregatesHiroo Yamaguchi, Yuji Nishimura, Dai Matsuse, et al.
Multiple Sclerosis and Related Disorders|April 9, 2025
Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart reviewKazuo Fujihara, Noriko Isobe, Katsuichi Miyamoto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2026
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)Kazuo Fujihara, Noriko Isobe, Katsuichi Miyamoto, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2023
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosisDavid Leppert, Mitsuru Watanabe, Sabine Schaedelin, et al.
European Journal of Medical Genetics|December 9, 2023
Progressive myoclonic epilepsy as an expanding phenotype of NGLY1-associated congenital deglycosylation disorder: A case report and review of the literatureYuri Sonoda, Atsushi Fujita, Michiko Torio, et al.
JAMA Neurology|June 1, 2016
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple SclerosisNoriko Isobe, Anisha Keshavan, Pierre-Antoine Gourraud, et al.
Neurology|June 18, 2013
Genetic risk variants in African Americans with multiple sclerosisNoriko Isobe, Pierre-Antoine Gourraud, Hanne F Harbo, et al.
Acta Neuropathologica Communications|September 24, 2025
Facilitated α-synuclein oligomer sharing among glial cells by a centrally acting connexin inhibitor attenuates a rapidly progressive multiple system atrophy-cerebellar type model by reducing the neuronal α-synuclein burdenMasaya Harada, Katsuhisa Masaki, Tatsunori Tanaka, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Scientific Reports|October 10, 2020
Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-AmericansNathan Nakatsuka, Nick Patterson, Nikolaos A Patsopoulos, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 11, 2023
Anti-LGI4 Antibody Is a Novel Juxtaparanodal Autoantibody for Chronic Inflammatory Demyelinating PolyneuropathyXu Zhang, Jun-Ichi Kira, Hidenori Ogata, et al.
Brain, Behavior, and Immunity|July 10, 2024
A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of α-synuclein oligomers and phosphorylated α-synuclein aggregatesHiroo Yamaguchi, Yuji Nishimura, Dai Matsuse, et al.
Multiple Sclerosis and Related Disorders|April 9, 2025
Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart reviewKazuo Fujihara, Noriko Isobe, Katsuichi Miyamoto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2026
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)Kazuo Fujihara, Noriko Isobe, Katsuichi Miyamoto, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2023
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosisDavid Leppert, Mitsuru Watanabe, Sabine Schaedelin, et al.
European Journal of Medical Genetics|December 9, 2023
Progressive myoclonic epilepsy as an expanding phenotype of NGLY1-associated congenital deglycosylation disorder: A case report and review of the literatureYuri Sonoda, Atsushi Fujita, Michiko Torio, et al.
JAMA Neurology|June 1, 2016
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple SclerosisNoriko Isobe, Anisha Keshavan, Pierre-Antoine Gourraud, et al.
Neurology|June 18, 2013
Genetic risk variants in African Americans with multiple sclerosisNoriko Isobe, Pierre-Antoine Gourraud, Hanne F Harbo, et al.
Acta Neuropathologica Communications|September 24, 2025
Facilitated α-synuclein oligomer sharing among glial cells by a centrally acting connexin inhibitor attenuates a rapidly progressive multiple system atrophy-cerebellar type model by reducing the neuronal α-synuclein burdenMasaya Harada, Katsuhisa Masaki, Tatsunori Tanaka, et al.
Pageof 15